Publications in collaboration with researchers from Centro de Investigación Médica Aplicada (36)

2024

  1. Identification of PRMT5 as a therapeutic target in cholangiocarcinoma

    Gut

2023

  1. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  2. Hepatocyte dedifferentiation profiling in alcohol-related liver disease identifies CXCR4 as a driver of cell reprogramming

    Journal of Hepatology, Vol. 79, Núm. 3, pp. 728-740

2022

  1. Next-generation sequencing of bile cell-free DNA for the early detection of patients with malignant biliary strictures

    Gut, Vol. 71, Núm. 6, pp. 1141-1151

2021

  1. Dual Targeting of G9a and DNA Methyltransferase-1 for the Treatment of Experimental Cholangiocarcinoma

    Hepatology, Vol. 73, Núm. 6, pp. 2380-2396

  2. Epigenetic mechanisms and metabolic reprogramming in fibrogenesis: Dual targeting of G9a and DNMT1 for the inhibition of liver fibrosis

    Gut, Vol. 70, Núm. 2, pp. 388-400

  3. Fragile X mental retardation protein in intrahepatic cholangiocarcinoma: regulating the cancer cell behavior plasticity at the leading edge

    Oncogene, Vol. 40, Núm. 23, pp. 4033-4049

  4. The splicing regulator SLU7 is required to preserve DNMT1 protein stability and DNA methylation

    Nucleic Acids Research, Vol. 49, Núm. 15, pp. 8592-8609

2020

  1. Pilot multi-omic analysis of human bile from benign and malignant biliary strictures: A machine-learning approach

    Cancers, Vol. 12, Núm. 6, pp. 1-30

2019

  1. Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis

    Nature Communications, Vol. 10, Núm. 1

  2. Splicing events in the control of genome integrity: Role of SLU7 and truncated SRSF3 proteins

    Nucleic Acids Research, Vol. 47, Núm. 7, pp. 3450-3466

2018

  1. Bile acids, FGF15/19 and liver regeneration: From mechanisms to clinical applications

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1864, Núm. 4, pp. 1326-1334

2017

  1. Engineered fibroblast growth factor 19 protects from acetaminophen-induced liver injury and stimulates aged liver regeneration in mice

    Cell Death and Disease, Vol. 8, Núm. 10

  2. Fibroblast growth factor 15/19 (FGF15/19) protects from diet-induced hepatic steatosis: Development of an FGF19-based chimeric molecule to promote fatty liver regeneration

    Gut, Vol. 66, Núm. 10, pp. 1818-1828

  3. Prioritizing Popular Proteins in Liver Cancer: Remodelling One-Carbon Metabolism

    Journal of Proteome Research, Vol. 16, Núm. 12, pp. 4506-4514

2016

  1. Splicing regulator SLU7 preserves survival of hepatocellular carcinoma cells and other solid tumors via oncogenic miR-17-92 cluster expression

    Oncogene, Vol. 35, Núm. 36, pp. 4719-4729

2015

  1. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development

    International Journal of Cancer, Vol. 136, Núm. 10, pp. 2469-2475

  2. Matrix Metalloproteinase 10 Contributes To Hepatocarcinogenesis in a Novel Crosstalk With the Stromal Derived Factor 1/C-X-C Chemokine Receptor 4 Axis

    Hepatology, Vol. 62, Núm. 1, pp. 166-178

2014

  1. Matrix metalloproteinase-10 expression is induced during hepatic injury and plays a fundamental role in liver tissue repair

    Liver International, Vol. 34, Núm. 7

  2. Splicing regulator SLU7 is essential for maintaining liver homeostasis

    Journal of Clinical Investigation, Vol. 124, Núm. 7, pp. 2909-2920